Published on
Roflumilast 0.05% cream, a new once-daily, steroid-free treatment that can be used anywhere on the body, was approved by the Food and Drug Administration to treat mild to moderate atopic dermatitis in children 2 to 5 years of age. According to the manufacturer’s press release, roflumilast can be used for any duration of time, which can be a benefit because the topical steroids that have been a standard treatment are not appropriate for long-term use. In clinical trials, roflumilast 0.05% cream improved the severity and extent of atopic dermatitis signs and symptoms, with approximately 40% of children achieving a 75% improvement and 35% achieving a clinically meaningful improvement in itch intensity in 4 weeks.
More information: The commercial product is expected to be available by the end of this month. Prescriber information can be found on the Arcutis Biotherapeutics website.